Souhaitez-vous accéder aux communiqués récents ?
Créez un compte lecteur dès aujourd’hui afin de suivre les secteurs et les entreprises qui vous intéressent, et configurer votre tableau de bord.
-
FDA alignment on a single-dose Phase 3 study design and potential single-trial registration pathway further strengthens the Company's clinical development program for urcosimodCompany unveils NEPTUNE...
-
Both parties intend to approach the collaboration in a spirit of openness, scientific rigor, and shared problem-solving, with the goal of advancing PRP
-
Nu-Tek will present data showing how its animal-free culture media nutrients improve yield, enhance processes, and strengthen supply security at SIMB 2026.
-
Hot Line Presentation of Primary Results from ACACIA-HCM to Elaborate on Positive Topline Results in Patients with Non-Obstructive Hypertrophic Cardiomyopathy Company to Host In-Person and Virtual...
-
Annovis Reaches Full Enrollment in Pivotal Phase 3 Trial of Buntanetap for Early Alzheimer’s Disease
Pivotal Phase 3 trial enrolls 850 patients, exceeding original projections Study completion on track: symptomatic data readout - Q1 2027, disease-modifying data readout - Q1 2028 Company positions...
-
SAN DIEGO, July 07, 2026 (GLOBE NEWSWIRE) -- ImageneBio, Inc. (Nasdaq: IMA, “Imagene” or the “Company”), today announced the appointment of Matt Robbins, an experienced life sciences attorney with...
-
Marie Washburn appointed CFO at Longeveron.
-
PharmAla announces the completion of manufacture of ALA-002 drug substance, as well as a full operational update on the LaNeo Gen 2 patented drug family.
-
Pluristyx secures a Series A priced round initial close led by a multinational Fortune 500 company to accelerate growth and expand its stem cell platform.
-
ICP-B208 is InnoCare's second ADC from its in-house platform to enter clinical development. There are no approved CDH17 targeted ADCs globally.